Analysis Tools
growth/size/body
|
• both sexes show a significantly lower body weight than wild-type controls at 16 weeks of age, but not at earlier time points
• however, average daily food intake is normal in both sexes
|
cardiovascular system
| N |
• mice show normal retinal vascular development (large vessels sprouting, branching vessels, tortuosity, vessel dilatation, and hemorrhages) relative to wild-type controls
• vascular permeability is unaffected, as measured by Evans blue dye leakage in lung, liver and ear
|
|
• at day 15 after s.c. injection of B16F10 melanoma cells, the number of CD31-positive microvessels within tumor tissue is lower than that in wild-type controls, indicating impaired tumor angiogenesis
• at day 18 after s.c. injection of B16F10 cells, the number of mature (both CD31-positive and smooth muscle actin (SMA)-positive) microvessels is significantly lower than that observed at day 15 in wild-type controls
• impaired tumor angiogenesis and microvessel maturation is also noted following s.c. injection of Lewis Lung carcinoma (LLC) cells or fat pad injection of E0771 breast cancer cells
|
|
• at day 7 after implantation of Matrigel plugs in the flank region, hemoglobin content in the excised Matrigel is reduced by 59% relative to that in wild-type controls, indicating decreased angiogenesis
• ex vivo, aortic rings cultured in Matrigel show significantly less endothelial cell sprouting relative to wild-type rings
|
neoplasm
|
• at day 15 after s.c. injection of B16F10 melanoma cells, the number of CD31-positive microvessels within tumor tissue is lower than that in wild-type controls, indicating impaired tumor angiogenesis
• at day 18 after s.c. injection of B16F10 cells, the number of mature (both CD31-positive and smooth muscle actin (SMA)-positive) microvessels is significantly lower than that observed at day 15 in wild-type controls
• impaired tumor angiogenesis and microvessel maturation is also noted following s.c. injection of Lewis Lung carcinoma (LLC) cells or fat pad injection of E0771 breast cancer cells
|
|
• following s.c. injection of B16F10 melanoma cells, mice show a 45% decrease in B16F10 tumor volume at day 15, with significantly smaller tumor volumes after day 6 of injection
• at day 18 after s.c. injection of B16F10 cells, tumor volume is similar to that observed at day 15 in wild-type controls
• a significant reduction in tumor growth is also noted following s.c. injection of Lewis Lung carcinoma (LLC) cells or fat pad injection of E0771 breast cancer cells
|
